BioLineRx (BLRX) Total Debt (2015 - 2025)

BioLineRx's Total Debt history runs 11 years deep, the most recent figure standing at $8.9 million for Q4 2025.

• In Q4 2025, Total Debt fell 33.47% year-over-year to $8.9 million; the TTM figure through Dec 2025 stood at $8.9 million (down 33.47% YoY), while the FY2025 annual figure was $8.9 million, down 33.47% from the prior year.
• Total Debt was $8.9 million for Q4 2025 at BioLineRx, down from $10.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $29.4 million in Q2 2024 to a low of $1.0 million in Q2 2022.
• Historically, Total Debt has averaged $10.2 million across 5 years, with a median of $9.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Debt tumbled 76.77% in 2022, then surged 1042.45% in 2023.
• A 5-year view of Total Debt shows it stood at $2.8 million in 2021, then surged by 268.81% to $10.2 million in 2022, then dropped by 3.88% to $9.8 million in 2023, then surged by 37.49% to $13.4 million in 2024, then slumped by 33.47% to $8.9 million in 2025.
• The last three Total Debt figures came in at $8.9 million (Q4 2025), $10.1 million (Q3 2025), and $11.2 million (Q2 2025), per Business Quant data.